$-0.05
(Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-9 Mln
-
ROE
-15.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
42,084,264
6 Years Aggregate
CFO
$-25.17 Mln
EBITDA
$-52.19 Mln
Net Profit
$-52.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Scopus Biopharma Inc (SCPS)
| -- | -- | -- | -- | -79.7 | -84.8 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Scopus Biopharma Inc (SCPS)
| -94.0 | -89.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Scopus Biopharma Inc (SCPS)
|
0.0 | 0.0 | 0.0 | -8.0 | -- | -- | -- | 2.4 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.2 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.3 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 350.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 534.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 142.6 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Scopus Biopharma Inc (SCPS)
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of... transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York. Read more
-
Senior Advisor & Director
Mr. Ira Scott Greenspan
-
Senior Advisor & Director
Mr. Ira Scott Greenspan
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Scopus Biopharma Inc (SCPS)
What is the current share price of Scopus Biopharma Inc (SCPS) Today?
The share price of Scopus Biopharma Inc (SCPS) is $0.00 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Scopus Biopharma Inc (SCPS) has given a return of -79.73% in the last 3 years.
What is the current PB & PE ratio of Scopus Biopharma Inc (SCPS)?
Since, TTM earnings of Scopus Biopharma Inc (SCPS) is negative, P/E ratio is not available.
The P/B ratio of Scopus Biopharma Inc (SCPS) is 2.42 times as on 21-Aug-2026, a 55 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.18 |
-0.29 |
2021 |
-1.35 |
8.58 |
2020 |
-19.21 |
-121.36 |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Scopus Biopharma Inc (SCPS)?
The 52-week high and low of Scopus Biopharma Inc (SCPS) are Rs 0.00 and Rs 0.00 as of 29-Aug-2026.
What is the market cap of Scopus Biopharma Inc (SCPS)?
Scopus Biopharma Inc (SCPS) has a market capitalisation of $ 0 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Scopus Biopharma Inc (SCPS)?
Before investing in Scopus Biopharma Inc (SCPS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.